<p>AstraZeneca announced that injectable derazantinib (Dazhuoyou) has officially been approved in China for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer who have previously received endocrine therapy and at least one line of chemotherapy in the advanced disease stage.
Derazantinib is a targeted TROP2 antibody-drug conjugate (ADC) and is the second ADC drug developed in collaboration between AstraZeneca and Daiichi Sankyo to be introduced in China. (The Paper)</p>

<p>Astrazeneca announced that its second ADC drug, datopotamab deruxtecan (Dato-DXd), has been approved in China for the treatment of specific types of advanced breast cancer patients. The drug is suitable for adult patients with unresectable or metastatic hormone receptor-positive, HER2-negative breast cancer who have previously received endocrine therapy and experienced at least one line of chemotherapy. Datopotamab deruxtecan is a TROP2-targeting antibody-drug conjugate developed in collaboration between Astrazeneca and Daiichi Sankyo</p>

Astrazeneca's second ADC drug has been approved for breast cancer in China